Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

November 17, 2026

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Classification of US FDA Inspection at the facility of Caplin Steriles Limited (Company's Subsidiary) as OAI – Reg

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that further to the United States Food and Drug Administration (US FDA) unannounced inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi between August 13, 2026, and August 21, 2026 which concluded with 10 observations that were procedural in nature, the US FDA has now determined that the inspection classification of the Caplin Steriles Limited facility is "Official Action Indicated" (OAI).

The Company does not expect any material impact on its financials or operations on account of the above as on the date of this intimation. The facility continues to manufacture and supply products and the Company remains committed to maintaining the highest standards of quality, current Good Manufacturing Practices (cGMP) and regulatory compliance. The company is committed to working closely with the FDA to address the observations and demonstrate the effectiveness and sustainability of corrective and preventive actions.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

The details required to be disclosed under Part A of Schedule III of the SEBI LODR Regulations, to the extent applicable, are set out in the Annexure to this intimation.

Kindly take the same on your records.

Sincerely Yours,

For Caplin Point Laboratories Limited

VENKATRAM GANAPATHISUBRAMANIAN

Digitally signed by VENKATRAM GANAPATHISUBRAMANIAN
Date: 2026.11.17 13:47:26 +05'30'

Venkatram G
General Counsel & Company Secretary
Membership No A23989

Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

ANNEXURE

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details
1	Name of the authority	US Food and Drug Administration (US FDA), USA
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (US FDA) inspected Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi from August 13, 2026 to August 21, 2026. The inspection had concluded with 10 procedural observations.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	November 16, 2026
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed	The US FDA has now determined that the inspection classification of this facility is "Official Action Indicated" (OAI).
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financials or operations due to the said action.